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At the heart of precision medicine lies the goal of optimizing care to ensure that the “right treatments 
are delivered to the right patient at the right time”.  Precision pharmacotherapy is an important 
component of precision medicine and is the focus of this special issue. Components of precision 
medicine related to pharmacotherapy may include: -omic approaches to identifying optimal drug 
therapies for patients based on molecular (DNA, RNA, protein) profiles, treatments targeting specific 
molecular components of disease pathology, and personalized dosing using individual kinetic profiles 
which are the combination of physiological, environmental, and genetic characteristics of a patient. As 
highlighted in this special issue, a call for contributions in the area of ‘precision medicine’ resulted in 
great interest focusing on the –omics (pharmacogenomics, metabolomics) aspects of precision 
medicine.  
Looking at precision medicine with a broader lens, many would say that the personalized medicine 
mantra has been a key component of clinical pharmacology since its inception. The difference, now 
being that scientific discovery has allowed for pharmacotherapy optimization in many new and exciting 
ways based on the integration of new technologies.  An example of this is that the Food and Drug 
Administration (FDA) now lists more than 160 medications which contain specific pharmacogenomic 
information within their package inserts (1,2). As highlighted in this issue, approximately 100 of these 
medications possess potentially ‘actionable’ pharmacogenomic information [Drozda ref]. Notable 
challenges about how to put this into practice have informed study designs moving forward with an 
increasing number of drugs approved with companion diagnostic tests.    
Now that we are more than 10 years beyond completion of the human genome project, current work 
focusing on the optimization of treatment' for a specific patient's illness, is really building upon the 
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foundation started by the field of pharmacogenomics (3).  While there are some examples in which a 
few genetic variants have been deemed essential in determining drug response, this has become the 
exception rather than the rule, and as such the field has begun to evolve in to utilizing a more 
comprehensive approach, one that includes more than genomics, and as of late has been coined 
“precision medicine” or “precision health”.  Therefore in this special issue of Pharmacotherapy, our goal 
has been to broadly represent work being done, which can be seen by the broad depth of articles we 
have chosen for inclusion. 
This evolution from pharmacogenomics to precision medicine has been driven by advancements in our 
knowledge of disease mechanisms which has improved treatments for complex illnesses. These 
advances have been supported by a general research sharing infrastructure provided by the National 
Institutes of Health.  In 2000, the NIH supported the creation of the Pharmacogenomics Knowledge Base 
(PharmGKB) and the Pharmacogenomics Research Network (PGRN), which currently still serves as a 
primary resource for pharmacogenomic information.  In fact, the partnership between PharmGKB and 
the PGRN has resulted in the establishment of the Clinical Pharmacogenomics Implementation 
Consortium (CPIC), which provides clinical practice guidelines for the interpretation of 
pharmacogenomic results, as it recognized early that guidelines were needed to help clinicians make 
rational prescribing decisions based on pharmacogenomic information (4).  Recently work has described 
that 1 out of 4 pharmacogenomics test results had a potential clinically actionable outcome, which 
shows the possible impact on patient care (5).  Currently there are more than 43 gene/drug pairs for 
which CPIC has provided guidelines. However there are many more gene/drug pair combinations that 
are either in progress or may benefit from a consensus evaluation (https://cpicpgx.org/genes-drugs/).  
Internationally, other organizations are also working to advance clinically-relevant pharmacogenomic 
knowledge. These include the Dutch Pharmacogenomics Working Group 
(https://www.pharmgkb.org/page/dpwg), and the European Pharmacogenomics Implementation 
Consortium (http://www.eu-pic.net/) which also provide pharmacogenomics resources and guidelines.   
Advancing pharmacotherapy aspects of precision medicine requires research across the translational 
spectrum. Our goal in assembling this special issue was to present diverse examples of this work. 
Discovery research which identifies and characterizes gene-drug relationships provides a scientific 
foundation for clinical advancements. Examples in this issue include discovery metabolomics research in 
sepsis, the identification genetic loci related to drug sensitivity reactions, and characterizing the clinical 
pharmacology implications of drug metabolism genetics. Identifying available studies and harmonizing 
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results from differing populations in study designs is an essential part of advancing the field. Highlighted 
in this issue are therapeutically-relevant reviews related to antidepressants, antiretrovirals, statins, 
diabetes, opioids, and cancer treatments that provide comprehensive updates of pharmacogenomic 
information in areas where clinical tests are now available, but have largely not yet been evaluated by 
guideline groups.  
The ‘holy grail’, so to speak, of the Human Genome Project, has long been to directly advance patient 
care. However the evolution of knowledge about the human genome to pharmacology-related discovery 
and finally to clinical application has taken longer than originally expected. The successful 
implementation of precision medicine in the clinic requires thoughtful, multidisciplinary research. 
Importantly this takes collaboration and the sharing of knowledge and resources. The PGRN  freely 
disseminates numerous on-line educational resources related to the principles behind 
pharmacogenomics, as well as additional implementation resources. The CPIC group has developed a 
software tool to extract all CPIC guidelines gene variants from a genetic dataset, interpret the alleles, 
and generate output for clinical decision support. Consortia such as the Electronic Medical Records and 
Genomics (eMERGE), and Implementing Genomics In Practice (IGNITE) as well as others provide 
research and resources related to clinical practice. Clinically relevant research and perspectives are also 
highlighted in this special issue. Examples include important information on how to choose a clinical lab 
for pharmacogenomic testing and using pharmacogenomic information to select novel therapies for 
tumors.  
It is very important to note that the science of precision medicine does not stop at the implementation 
of this work.  Work examining the best way to use this information within clinical practice is desperately 
needed, along with data identifying the best way to educate patient populations, as well as the 
providers utilizing pharmacogenomics as a “tool” within practice for the first time.  Perhaps the biggest 
misconception about pharmacogenomics is that the ‘answers’ provided by testing results are simple, 
when in fact this is not often the case.  Therefore, it is critical for every health care provider using 
pharmacogenomics within practice understand the nuances of this work and to be aware of all available 
resources as we usher in new practices in regards to patient care (6).
While this is a very exciting time for the field of precision health, more work being done by the NIH will 
hopefully propel us into the next stage of understanding the impact of precision medicine in practice 
through the creation of the “All of Us” program which “will enable a new era of medicine in which 
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researchers, health care providers, and patients work together to develop individualized care.” 
(https://allofus.nih.gov/about/about-all-us-research-program).  By recruiting and analyzing samples 
from more than 1 Million individuals within the US, this participant engaged, and data driven research 
may just usher in the next generation of “Precision Health”.  Therefore, as previously stated the overall 
goal of pharmacogenomics and precision medicine is simple; provide the “right drug to the right patient 
at the right time.” By working together, we can make this vision a reality, as the practice of 
pharmacogenomics, or precisions medicine or precision health becomes the standard of care.   
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